BOK-AS1: A Potential Drug Target and Biomarker (G100379249)

Target Name: BOK-AS1

NCBI ID: G100379249

BOK-AS1

Other Name(s): NAToB | NCRNA00151 | BOK-AS | BOKAS | BOK antisense RNA 1

BOK-AS1: A Potential Drug Target and Biomarker

BOK-AS1 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. Its primary function is to regulate the growth and differentiation of epithelial cells, which are responsible for forming the lining of various body surfaces and organs. BOK-AS1 has been identified as a potential drug target and biomarker for various diseases, including cancer, obesity, and gastrointestinal diseases.

Disease-Related Role of BOK-AS1

BOK-AS1 is involved in several disease processes that are of significant impact on human health. One of the primary roles of BOK-AS1 is to regulate the growth and differentiation of epithelial cells. This is critical for the development and maintenance of various body surfaces and organs, including the skin, gut, and respiratory tract. BOK-AS1 plays a vital role in the development and progression of many diseases, including cancer, obesity, and gastrointestinal diseases.

Potential Drug Targets

BOK-AS1 has been identified as a potential drug target due to its involvement in several disease processes. One of the primary targets of BOK-AS1 is the regulation of cell growth and differentiation. BOK-AS1 has been shown to play a role in the regulation of stem cell proliferation and the development of cancer. BOK-AS1 has also been shown to be involved in the regulation of fetal development and has been linked to several diseases, including cancer and obesity.

In addition to its role in cell growth and differentiation, BOK-AS1 has also been shown to be involved in the regulation of immune responses and inflammation. BOK-AS1 has been shown to play a role in the regulation of T cell development and function, which is critical for the immune response. BOK-AS1 has also been shown to be involved in the regulation of inflammation and has been linked to several diseases, including cancer and obesity.

Biomarkers

BOK-AS1 has also been identified as a potential biomarker for several diseases. One of the primary biomarkers for BOK-AS1 is its expression level in various tissues and organs. This can be used to monitor the effectiveness of treatments for diseases associated with BOK-AS1, such as cancer and obesity.

Another biomarker for BOK-AS1 is its involvement in several diseases, including cancer and obesity. BOK-AS1 has been shown to be involved in the regulation of cancer cell growth and has been linked to the development of several types of cancer, including breast, ovarian, and prostate cancer. In addition, BOK-AS1 has also been shown to be involved in the regulation of obesity, which is a significant public health issue that can lead to a range of health problems, including cardiovascular disease, diabetes, and certain types of cancer.

Conclusion

In conclusion, BOK-AS1 is a protein that is expressed in various tissues of the body and plays a critical role in several disease processes. Its potential as a drug target and biomarker makes it an attractive target for research into the treatment of various diseases, including cancer, obesity, and gastrointestinal diseases. Further research is needed to fully understand the role of BOK-AS1 in disease and to develop effective treatments.

Protein Name: BOK Antisense RNA 1

The "BOK-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BOK-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets